Can EU Label Expansions of NVO's GLP-1 Drugs Spur Sales Growth?
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Open original sourceLoading market dashboard
Novo Nordisk's EU label expansions may widen semaglutide use and boost volumes, but pricing pressure and Lilly rivalry can limit recovery.
Open original source